Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
5.39
+0.02 (0.37%)
At close: Apr 24, 2026, 4:00 PM EDT
5.50
+0.11 (2.04%)
After-hours: Apr 24, 2026, 4:19 PM EDT
Aardvark Therapeutics Employees
Aardvark Therapeutics had 40 employees as of December 31, 2025. The number of employees increased by 18 or 81.82% compared to the previous year.
Employees
40
Change
18
Growth
81.82%
Revenue / Employee
n/a
Profits / Employee
-$1,439,775
Market Cap
117.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 40 | 18 | 81.82% | 40 | 0 |
| Sep 30, 2025 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2025 | 31 | 17 | 121.43% | 31 | 0 |
| Mar 31, 2025 | 26 | 12 | 85.71% | 26 | 0 |
| Dec 31, 2024 | 22 | - | - | 22 | 0 |
| Sep 30, 2024 | 18 | - | - | 17 | 1 |
| Jun 30, 2024 | 14 | - | - | 12 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 174 |
| Cibus | 118 |
| Immunic | 92 |
| Verrica Pharmaceuticals | 76 |
| Pyxis Oncology | 56 |
| Vivani Medical | 42 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 29 |
AARD News
- 3 days ago - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - PRNewsWire
- 11 days ago - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewsWire
- 4 weeks ago - Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 7 weeks ago - AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 7 weeks ago - What's Going On With Aardvark Therapeutics Stock On Wednesday? - Benzinga
- 7 weeks ago - Why Is Aardvark Therapeutics Stock Sinking Monday? - Benzinga
- 2 months ago - AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire